Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis

Blauvelt A, Green LJ, Lebwohl MG, Yamauchi PS, Lin T, Martin G, Pillai R.

J Drugs Dermatol. 2019 Mar 1;18(3):297-299.

PMID:
30909352
2.
3.

Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.

Stein Gold L, Kircik LH, Pariser D, Sugarman JL, Lin T, Kang R, Pillai R.

J Drugs Dermatol. 2018 Aug 1;17(8):863-868.

PMID:
30124725
4.

Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis

Kircik LH, Papp KA, Stein Gold L, Harris S, Pharm TL, Pillai R.

J Drugs Dermatol. 2019 Mar 1;18(3):279-284..

PMID:
30909333
5.

Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.

Sugarman JL, Weiss J, Tanghetti EA, Bagel J, Yamauchi PS, Stein Gold L, Lin T, Martin G, Pillai R, Israel R.

J Drugs Dermatol. 2018 Aug 1;17(8):855-861.

PMID:
30124724
6.

Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis

Stein Gold L, Bagel J, Lebwohl M, Lin T, Martin G, Pillai R.

J Drugs Dermatol. 2018 Dec 1;17(12):1290-1296.

PMID:
30586261
7.

Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.

Pariser DM, Green LJ, Stein Gold L, Sugarman JL, Lin T, Pillai R.

J Drugs Dermatol. 2018 Jul 1;17(7):723-726.

PMID:
30005093
8.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.

Gold LS, Lebwohl MG, Sugarman JL, Pariser DM, Lin T, Martin G, Pillai R, Israel R, Ramakrishna T.

J Am Acad Dermatol. 2018 Aug;79(2):287-293. doi: 10.1016/j.jaad.2018.03.040. Epub 2018 Apr 1.

9.
10.

Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.

Green LJ, Kerdel FA, Cook-Bolden FE, Bagel J, Lin T, Martin G, Pillai R, Israel R, Ramakrishna T.

J Drugs Dermatol. 2018 Oct 1;17(10):1062-1069.

PMID:
30365586
12.

Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis.

Lebwohl MG, Sugarman JL, Gold LS, Pariser DM, Lin T, Pillai R, Martin G, Harris S, Israel R.

J Am Acad Dermatol. 2019 Jan;80(1):282-285. doi: 10.1016/j.jaad.2018.09.002. Epub 2018 Sep 15. No abstract available.

13.
14.

Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque Psoriasis.

Pariser D, Bukhalo M, Guenthner S, Kempers S, Shideler S, Gold LS, Tschen E, Berg J, Ferdon MB, Dromgoole S.

J Drugs Dermatol. 2017 Mar 1;16(3):234-240.

PMID:
28301619
15.

Safety and efficacy of halobetasol propionate lotion 0.01% in the treatment of moderate to severe plaque psoriasis: a pooled analysis of 2 phase 3 studies.

Sugarman JL, Weiss JS, Tanghetti EA, Soung J, Yamauchi PS, Lin T, Harris S, Martin G, Pillai R.

Cutis. 2019 Feb;103(2):111-116.

PMID:
30893392
19.

Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities

Bhatia ND, Vlahovic TC, Green LG, Martin G, Lin T.

J Drugs Dermatol. 2019 Oct 1;18(10):1029-1036.

PMID:
31584782
20.

Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.

Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, Lew-Kaya DA, Sefton J, Gibson JR, Walker PS; Tazarotene Cream Clinical Study Group.

J Am Acad Dermatol. 2003 May;48(5):760-7.

PMID:
12734506

Supplemental Content

Support Center